Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus R-CHOP for previously untreated non-germinal center diffuse large B-cell lymphoma
2019-001755-39Phase 3Active
- Sponsor
- Acerta Pharma
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Acalabrutinib + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival. Started Sep 2020; status: active.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2019-001755-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001755-39.